Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer
Giulio Metro(University of Perugia), F. Cognetti(Sapienza University of Rome), Alessandra Fabi(Agostino Gemelli University Polyclinic), Gaetano Lanzetta(IRCCS Istituto Auxologico Italiano), Emanuela Magnolfi(Accademia di Belle Arti di Frosinone), V. Lorusso(Gastroenterology Hospital "Saverio de Bellis"), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Donatello Gemma, Mariangela Ciccarese(Ospedale Vito Fazzi)
Cited by 3
Related Papers
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240